Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
Status:
Active, not recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well apalutamide works in treating patients with prostate
cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells.
Hormone therapy using apalutamide may fight prostate cancer by lowering the amount of
androgen the body makes and may make it less likely for patients to receive radiation therapy
after surgery.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Janssen Scientific Affairs, LLC National Cancer Institute (NCI)